Linaclotide

• Irritable Bowel Syndrome with Constipation (IBS-C)
• Chronic Idiopathic Constipation
• Functional Constipation
• GI Motility Disorders

Linaclotide, sold as Linzess, is a peptide medication that treats two of the most common chronic gastrointestinal complaints in adult medicine: irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. It belongs to a small class of drugs called guanylate cyclase-C agonists, which work entirely within the lumen of the intestine to draw fluid into the bowel and accelerate transit. Because it is essentially not absorbed into the bloodstream, linaclotide has a clean systemic safety profile and minimal drug interactions, but it carries a strict pediatric contraindication, must be timed correctly relative to meals, and frequently produces diarrhea, the very effect on which its therapeutic action depends. For patients whose constipation has not responded to fiber, hydration, exercise, and over-the-counter laxatives, linaclotide offers a meaningful and well-studied option.

Mechanism of Action

Linaclotide is a synthetic 14-amino-acid peptide structurally related to endogenous guanylin and uroguanylin. Taken orally, it binds to and activates guanylate cyclase-C (GC-C) receptors on the apical surface of enterocytes lining the small intestine and colon. Activation of GC-C raises intracellular cyclic guanosine monophosphate (cGMP), which in turn opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and stimulates bicarbonate secretion through additional anion exchangers. The osmotic gradient created by chloride and bicarbonate secretion pulls water into the intestinal lumen, softening stool and accelerating transit time.

An additional and clinically important effect is on visceral pain. Elevated extracellular cGMP appears to dampen sensitization of submucosal afferent nerve fibers, reducing the heightened pain response to bowel distention that characterizes IBS. This dual action distinguishes linaclotide from osmotic laxatives such as polyethylene glycol, which improve bowel frequency but typically do not relieve abdominal pain. Plecanatide, a related GC-C agonist, shares this mechanism with subtle differences in pH-dependent activity. Less than 1 percent of an oral dose is absorbed systemically, so plasma levels remain effectively undetectable. The peptide is digested in the small bowel into smaller fragments and the active metabolite is similarly poorly absorbed. This means clearance does not depend on the kidneys or liver, and the medication does not engage cytochrome P450 enzymes or interact pharmacokinetically with other oral drugs. Background information on bowel disorder pathophysiology is available from the American Gastroenterological Association.

Clinical Use

For chronic idiopathic constipation, treatment guidelines from the American College of Gastroenterology recommend a stepped approach: lifestyle and dietary changes first, then over-the-counter agents such as polyethylene glycol or psyllium, followed by prescription secretagogues like linaclotide, plecanatide, or lubiprostone, or the prokinetic prucalopride for refractory cases. For IBS-C, linaclotide is one of two first-line prescription options (with plecanatide), reflecting its strong evidence for both bowel-frequency and pain endpoints. Clinical trials demonstrated significant improvement in spontaneous bowel movements per week, stool consistency on the Bristol scale, abdominal pain, bloating, and global IBS symptoms compared with placebo.

Patient selection favors adults with infrequent bowel movements (fewer than three per week), straining, sensation of incomplete evacuation, and bothersome abdominal discomfort. Patients with predominant diarrhea, mixed-pattern IBS, or inflammatory bowel disease are not candidates. Linaclotide is not a rescue medication and does not produce immediate effect; benefit accumulates over one to four weeks of consistent dosing. Compared with lubiprostone, linaclotide tends to produce less nausea but more diarrhea. Compared with prucalopride, linaclotide does not improve transit times in the upper gut and is best for distal constipation symptoms. For patients with predominantly opioid-induced constipation, naloxegol or methylnaltrexone are typically preferred over linaclotide. Our gastrointestinal team often coordinates with primary care to titrate therapy and manage breakthrough symptoms.

How to Take It

Linaclotide capsules come in 72 mcg, 145 mcg, and 290 mcg strengths. The recommended dose for IBS-C in adults is 290 mcg once daily; for chronic idiopathic constipation, the starting dose is 145 mcg once daily, with 72 mcg available for those who experience excessive diarrhea but still need treatment. The capsule is taken on an empty stomach at least 30 minutes before the first meal of the day. Taking it with food or shortly before a meal substantially increases the rate of loose stools, often within an hour, which can interfere with the workday. Many patients find that taking the capsule with a glass of water immediately upon waking, then proceeding with morning routines before breakfast, works best.

Capsules are usually swallowed whole. If swallowing is difficult, the capsule can be opened and the beads sprinkled on one teaspoon of room-temperature applesauce or mixed in approximately 30 mL of bottled water and consumed immediately. Beads must not be chewed or crushed. If a dose is missed, skip it and take the next dose at the usual time the following morning; do not double up. Store at room temperature in the original bottle with the desiccant packet to protect from moisture. During the first week, expect more frequent and softer bowel movements, often within 6 to 24 hours of the first dose. Mild abdominal cramping and bloating are common initially and usually settle. If diarrhea is severe (more than three loose watery stools per day or any sign of dehydration), stop the medication and contact the office.

Monitoring and Follow-Up

Linaclotide does not require any specific blood test monitoring because it is not systemically absorbed. Clinical follow-up focuses on symptom-based response: stool frequency, consistency on the Bristol Stool Scale (target 3 to 5), abdominal pain, bloating, and overall functional improvement. A reasonable assessment timeline is 2 to 4 weeks after initiation, then quarterly, with adjustment of dose if symptoms remain inadequate or side effects intolerable. Patients are encouraged to keep a brief diary noting bowel movements, stool form, pain severity (0 to 10 scale), and any breakthrough laxative use, particularly during the first month.

Red flags during therapy include severe persistent diarrhea, bloody stools, unintentional weight loss, fever, severe abdominal pain that is different in character from the patient's usual IBS pattern, new onset of nighttime symptoms, anemia, or any symptom suggesting inflammatory bowel disease or malignancy. These warrant in-office evaluation and may require colonoscopy. Although there are no required labs, baseline electrolytes are reasonable in older adults or those with kidney or heart disease who could be sensitive to volume shifts from severe diarrhea. There is no specific maximum duration of therapy; many patients use linaclotide long-term safely. Periodically, attempts to taper or discontinue may be reasonable to reassess underlying need.

Special Populations

Linaclotide is contraindicated in patients younger than 2 years of age because of fatal dehydration and intestinal toxicity observed in neonatal mouse studies, and use is not recommended in patients aged 2 through 17 years pending more safety data. In adults aged 65 and older, no dose adjustment is required, but older patients are more susceptible to electrolyte imbalances if diarrhea occurs and should be monitored carefully, especially if they take diuretics or have cardiovascular disease. Renal impairment, including dialysis, does not require dose change because the peptide is not absorbed.

Hepatic impairment likewise does not change dosing. Pregnancy data are limited; animal reproductive studies showed no harm at exposures far above human therapeutic levels, but use in pregnancy is reserved for cases where benefits clearly outweigh risks. Breastfeeding is generally considered low-risk because linaclotide is not appreciably absorbed and is therefore unlikely to enter breast milk in clinically relevant amounts. Patients with known or suspected mechanical gastrointestinal obstruction must not take linaclotide, as accelerated transit and fluid secretion above an obstruction can be dangerous. Caution is also warranted in patients with severe debilitation, severe gastrointestinal motility disorders other than constipation, and recent abdominal surgery.

When to Contact Your Doctor

Call the office for severe diarrhea (more than three loose stools per day, watery diarrhea, or signs of dehydration including dizziness, dark urine, or marked thirst), bloody or black stools, severe persistent abdominal pain, fever, unintentional weight loss, or vomiting that prevents fluid intake. Significant lightheadedness, fainting, palpitations, or muscle cramps may indicate electrolyte disturbance from volume loss and warrant prompt evaluation. New rectal bleeding or a marked change in bowel pattern that does not resolve with dose reduction should be evaluated for other causes. Patients with kidney or heart disease who develop diarrhea should pause linaclotide and call sooner rather than later because they tolerate volume shifts poorly.

Any suspected pregnancy, planned breastfeeding, or new mechanical bowel symptoms should also be discussed before continuing therapy. If you are struggling with chronic constipation or IBS-C and want to discuss whether linaclotide fits your situation, contact us or schedule a visit. Detailed dosing tables, drug interactions, and frequently asked questions appear on this page below.